Human Immunodeficiency Virus | Treatment Algorithms: Claims Data Analysis | US | 2025

The HIV therapy market is crowded with many approved ARVs. Market growth is driven by the increasing acceptance of new, high-priced ARVs, particularly the latest STRs, that offer improved safety, tolerability, and reduced pill burden. The introduction of single-pill nuc-sparing and nuc-reduced regimens (e.g., ViiV’s Juluca and Dovato), which have a lower long-term risk of comorbidities, may expand treatment options and allow preferential prescribing to HIV patients who are compliant with their treatment regimens. Additionally, the approvals of ViiV’s Cabenuva in 2021 and Gilead’s Sunlenca in 2022 have ushered in a new era of long-acting regimens that will help eliminate the requirement for lifelong daily pills. This claims data analysis explores the usage patterns of these newer therapies relative to historical mainstays of treatment and provides valuable insight into evolving drug-treatment trends in HIV.

QUESTIONS ANSWERED

• What patient shares do key therapies and brands garner by line of therapy in newly diagnosed HIV patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed HIV patients?
• How have Biktarvy, Dovato, Juluca, Cabenuva, Sunlenca, and other been integrated into the treatment algorithm, and what are their sources of business?
• What percentage of HIV patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
• What percentage of HIV patients are treated with STRs versus multiple-tablet regimens? What are the most commonly used combinations?
• What are the product-level compliance and persistency rates among drug-treated patients?

PRODUCT DESCRIPTION

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data, enabling you to:

• Understand patient flow between lines of therapy.
• Evaluate your brand share against competitors.
• Accurately assess your source of business.

PRODUCT ENHANCEMENT

Treatment Algorithms: Claims Data Analysis leverages Clarivate’s proprietary Real-World Data, which brings larger patient samples, broader payer coverage, and faster availability for more robust and timely analyses. Additionally, we include new patient demographic analyses: age, gender, ethnicity, and region.

Markets covered: United States

Key drugs: Biktarvy, Dovato, Juluca, Delstrigo, Rukobia, Trogarzo, Cabenuva, Sunlenca

Key feature: Dashboard featuring interactive visuals, easy navigation, and expanded analyses